EMMPRIN and survivin: prognostic factors in cisplatin-treated patients with bladder cancer

被引：0
|
作者：
机构：
来源：
Nature Clinical Practice Oncology | 2007年 / 4卷 / 12期
关键词：
D O I：
10.1038/ncponc0938
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：676 / 676
相关论文
共 50 条
  • [31] Semen and serum platinum levels in cisplatin-treated survivors of germ cell cancer
    Malone, Eoghan R.
    Lewin, Jeremy
    Li, Xuan
    Zhang, Wen-Jiang
    Lau, Susan
    Jarvi, Keith
    Hamilton, Robert J.
    Hansen, Aaron R.
    Chen, Eric X.
    Bedard, Philippe L.
    CANCER MEDICINE, 2022, 11 (03): : 728 - 734
  • [32] Proteomics profile changes in cisplatin-treated human ovarian cancer cell strain
    LI Zhengyu1
    2. National Key Laboratory of Biotherapy of Human Diseases
    Science in China(Series C:Life Sciences), 2005, (06) : 648 - 657
  • [33] Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy
    Polee, MB
    Hop, WCJ
    Kok, TC
    Eskens, FALM
    van der Burg, MEL
    Splinter, TAW
    Siersema, PD
    Tillanus, HW
    Stoter, G
    van der Gaast, A
    BRITISH JOURNAL OF CANCER, 2003, 89 (11) : 2045 - 2050
  • [34] Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy
    M B Polee
    W C J Hop
    T C Kok
    F A L M Eskens
    M E L van der Burg
    T A W Splinter
    P D Siersema
    H W Tilanus
    G Stoter
    A van der Gaast
    British Journal of Cancer, 2003, 89 : 2045 - 2050
  • [35] Cardiovascular disease (CVD) risk factors among cisplatin-treated testicular cancer survivors (TCS): A multicenter clinical study of US and Canadian patients
    Fung, Chunkit
    Feldman, Darren Richard
    Hamilton, Robert James
    Case-Eads, Somer
    Vaughn, David J.
    Beard, Clair
    Moore, Malcolm J.
    Sahasrabudhe, Deepak M.
    Brames, Mary J.
    Fossa, Sophie D.
    Sesso, Howard D.
    Einhorn, Lawrence H.
    The, Lois B. Travis For
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [36] Survivin as prognostic and predictive factor in patients treated with gemcitabine, dexamethasone, and cisplatin for relapsed or refractory aggressive NHL
    Lamiss Mohamed Abd el Aziz
    Medical Oncology, 2014, 31
  • [37] Survivin as prognostic and predictive factor in patients treated with gemcitabine, dexamethasone, and cisplatin for relapsed or refractory aggressive NHL
    Abd el Aziz, Lamiss Mohamed
    MEDICAL ONCOLOGY, 2014, 31 (11) : 1 - 8
  • [38] PERITONEAL WASHING CYTOLOGY AT 2ND-LOOK LAPAROTOMY IN CISPLATIN-TREATED OVARIAN-CANCER PATIENTS
    KUDO, R
    TAKASHINA, T
    ITO, E
    MIZUUCHI, H
    SAGAE, S
    MORIWAKA, O
    TAMAGAWA, A
    ACTA CYTOLOGICA, 1990, 34 (04) : 545 - 548
  • [39] PROGNOSTIC FACTORS IN PATIENTS WITH BLADDER-CARCINOMA TREATED WITH DEFINITIVE IRRADIATION
    GREVEN, KM
    SOLIN, LJ
    HANKS, GE
    CANCER, 1990, 65 (04) : 908 - 912
  • [40] PROGNOSTIC FACTORS IN PATIENTS TREATED WITH INTRAVESICAL BACILLUS CALMETTE-GUERIN FOR SUPERFICIAL BLADDER-CANCER
    TORRENCE, RJ
    KAVOUSSI, LR
    CATALONA, WJ
    RATLIFF, TL
    JOURNAL OF UROLOGY, 1988, 139 (05): : 941 - 944
12345